Wugen
Wugen is a clinical-stage biotechnology company developing off-the-shelf cellular therapies for cancer, with research facilities in San Diego, CA, and St. Louis, MO.
Company Overview
Wugen is a clinical-stage biotechnology company focused on developing off-the-shelf cellular therapies for cancer. The company specializes in NK cell and CAR-T immuno-oncology therapies, utilizing healthy donors for cellular therapies. With research facilities located in San Diego, CA, and St. Louis, MO, Wugen conducts advanced research and development in the field of cancer treatment.
Products and Pipeline
Wugen's product pipeline features two major cell therapies: WU-CART-007 and WU-NK-101. WU-CART-007 is an allogeneic, off-the-shelf, fratricide-resistant CD7-targeted CAR-T cell therapy currently in a Phase 1/2 clinical trial for relapsed or refractory T-cell acute lymphoblastic leukemia/lymphoblastic lymphoma. WU-NK-101 is a memory NK cell therapy under development for acute myelogenous leukemia (AML). Both therapies have received various designations from the U.S. FDA, including Orphan Drug and Fast Track.
Technological Platforms
Wugen utilizes two proprietary platforms to advance cellular therapy manufacturing. The Moneta™ platform is designed for the production of memory NK cell therapies, optimizing these cells to enhance cancer cell elimination. Additionally, Wugen has signed a strategic platform license with MaxCyte, employing their Flow Electroporation® technology and ExPERT™ platform to improve the production and efficacy of CAR-T cells.
Clinical Trials and FDA Designations
WU-CART-007 and WU-NK-101 are both in various stages of development and have received multiple designations from the U.S. FDA. WU-CART-007 is in a Phase 1/2 clinical trial for T-cell acute lymphoblastic leukemia and lymphoblastic lymphoma and has received Orphan Drug, Fast Track, and Rare Pediatric Disease Designations. WU-NK-101 is being developed for AML and has attained Orphan Drug Designation for this indication.
Strategic Partnerships
Wugen has established strategic partnerships to bolster its manufacturing and research capabilities. The company collaborates with Cellipont Bioservices for the clinical manufacture of CAR-T cellular therapies. Additionally, their agreement with MaxCyte allows the utilization of sophisticated electroporation technology, enhancing the production process for their innovative cellular treatments.